Skip to main
MYGN

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 80%
Sell 20%
Strong Sell 0%

Bulls say

Myriad Genetics is facing challenges in terms of profitability, with concerns that the company may not be able to cut or grow its way into profitability. However, a potential increase in revenue growth and divestiture of certain divisions could improve its overall performance. Despite possessing good assets, there is a risk that strategic buyers may not view them as attractive enough for acquisition. Due to these challenges, the company has been downgraded to Underweight from Overweight, and the analyst suggests waiting to invest until there is a clear path to sustainable profitability.

Bears say

Myriad Genetics is facing significant challenges and a negative outlook due to continued weakness in their prenatal health segment, which is not being offset by growth in other areas. The company's recent underwhelming second quarter results and lowered guidance for the year suggest a more long-term commercial problem rather than just temporary issues. The arrival of a new CEO has not been enough to turn things around, and there are concerns about potential share loss and price compression in their hereditary cancer segment. Even if the company hits its revenue guidance, there may still be limited stock upside due to their operating profile.

Myriad Genetics (MYGN) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 80% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 5 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.